For more information, or to report problems registering, please contact The Exeter Group at 1-800-532-1344 (North America only) or +1-212-644-1017.

Supported by an educational grant from Bayer HealthCare AG and Ortho–McNeil Inc, Division of
Ortho–McNeil–Janssen Pharmaceuticals, Inc., administered by Ortho–McNeil Janssen Scientific Affairs, LLC.

Pre-registration is now closed.
Please register for the meeting on-site.

Faculty

Joseph S. Alpert, MD
Cochair

Professor of Medicine

Department of Medicine

Director of Coronary Care

The University of Arizona College of Medicine

Tucson, Arizona, United States

Michael D. Ezekowitz, MB ChB, DPhil
Cochair

Vice President and Professor

Lankenau Institute for Medical Research

Vice President, Clinical Research

Main Line Hospitals

Wynnewood, Pennsylvania, United States

Stephen E. Kimmel, MD, MSCE

Deputy Director, Clinical Epidemiology Unit

Associate Professor of Medicine & Epidemiology

Center for Clinical Epidemiology and Biostatistics

Director of Cardiovascular Epidemiology

Cardiovascular Division

University of Pennsylvania School of Medicine

Philadelphia, Pennsylvania, United States

Freek W. A. Verheugt, MD

Professor of Cardiology

HeartLung Centre

Universitair Medisch Centrum St. Radboud, Nijmegen

Chairman, Department of Cardiology

Onze Lieve Vrouwe Gasthuis

Amsterdam, The Netherlands

This event is not part of the official ACC Annual Scientific Session and/or the ACC’s Innovation in Intervention: i2 Summit in Partnership with the Cardiovascular Research Foundation, as planned by their Program Committees.

Agenda

6:00 – 6:45 pm
Registration and dinner

6:45 – 8:45 pm
Scientific program

Welcome and introduction

Joseph S. Alpert

Can pharmacogenetics save warfarin?

Stephen E. Kimmel

Dabigatran and stroke prevention

Michael D. Ezekowitz

Defining the potential of novel factor Xa inhibitors

Joseph S. Alpert

Complicating factors: Anticoagulant therapy in the complex patient

Freek W. A. Verheugt

Case presentations /
Panel discussion / Q & A

Moderator: Michael D. Ezekowitz

Closing remarks

Michael D. Ezekowitz

 

Target audience

This activity is intended for cardiologists and other health care professionals caring for patients with nonvalvular atrial fibrillation (AF) who are at risk of embolic stroke.

 

Educational objectives

At the completion of this activity, the participants should be able to:

  • Improve adherence to evidence-based guidelines concerning anticoagulant therapy in AF
  • Describe the results and implications of recently completed trials of anticoagulant agents in AF; integrate applicable results of these trials into patient care
  • Summarize the design and rationale of ongoing trials that will define the potential role of novel anticoagulants for stroke prevention in AF
  • Assess the implications of concomitant disease on anticoagulant therapy for preventing stroke in AF.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and The Exeter Group.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Cincinnati designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.

Physicians should only claim credits commensurate with the extent of their participation.

The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturers.

The University of Cincinnati is committed to retaining only those speakers with financial interests that can be resolved and reconciled with the goals and educational integrity of the CME program.